Newpath is a private venture capital investment fund focused on disruptive treatments and technologies in the life science space.
The firm is dedicated to improving science and to forming partnerships based on trust and a shared vision.
We search for innovative approaches across diverse fields including but not limited to pharmaceuticals, regenerative and personalized medicine, basic sciences, devices, drug discovery, cellular and gene therapies, robotics, AR/VR, and AI. With each investment, Newpath seeks to optimize performance by aligning the interests of academic founders, management teams, and investor groups.
People
- Erik Wold, Senior Director
You last contacted this investor on .